Ranger Biotechnologies A/S: Financial statements 2018
CVR: 32280404
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -831,940 and a net result of DKK -975,295 compared with DKK -4,850,000 the year before. Equity in the 2018 report amounted to DKK 13,370,483. The solvency ratio was 93.1%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -831,940
- Profit/Loss
- DKK -975,295
- Equity
- DKK 13,370,483
- Total Assets
- DKK 14,363,695
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -832K | -975K | 13.4M | 1 |
| 2017 | - | -1.3M | -4.9M | 14.3M | 1 |
| 2016 | - | 2.1M | 1.5M | 5.9M | 1 |
| 2015 | - | -733K | -633K | 4.4M | 1 |
| 2014 | - | -1.2M | -1.3M | 4.7M | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
On June 15, 2018, the company changed its name from MIRRX THERAPEUTICS A/S to Ranger Biotechnologies A/S.
Ranger Biotechnologies A/S has published its annual report for 2017. Gross profit came to DKK -1,274,000, and the net result was DKK -4,850,000.
As of May 25, 2018, SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of Ranger Biotechnologies A/S.
As of May 25, 2018, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Ranger Biotechnologies A/S.
As of May 25, 2018, Søren Tvede Larsen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Christina Møller Udesen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Kasper Tvede Larsen has joined the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Peter Buhl has left the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, John Riis Mortensen has left the board of directors of Ranger Biotechnologies A/S.
As of May 25, 2018, Jarne Elleholm has left the board of directors of Ranger Biotechnologies A/S.
About Ranger Biotechnologies A/S
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.